Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces Enterprise 3D Modeling Deal With AI Revenue Driving Growth (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L... see more

Recent & Breaking News (NDAQ:ELDN)

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

GlobeNewswire May 14, 2025

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

GlobeNewswire March 20, 2025

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

GlobeNewswire March 4, 2025

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

GlobeNewswire February 7, 2025

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire January 29, 2025

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

GlobeNewswire January 13, 2025

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

GlobeNewswire November 12, 2024

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

GlobeNewswire November 6, 2024

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire October 29, 2024

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

GlobeNewswire October 29, 2024

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

GlobeNewswire September 11, 2024

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

GlobeNewswire September 4, 2024

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

GlobeNewswire August 14, 2024

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

GlobeNewswire July 29, 2024

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

GlobeNewswire July 2, 2024

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

GlobeNewswire June 3, 2024

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

GlobeNewswire May 9, 2024

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

GlobeNewswire May 9, 2024

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

GlobeNewswire May 7, 2024

Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

GlobeNewswire May 7, 2024